PARIS & PALO ALTO, Calif.–(BUSINESS WIRE)–LBO France, a multi-specialist investment platform and pioneer in private equity, announced today the signing of a definitive agreement with Vivo Capital, a leading global investment firm focused exclusively on…
Suzhou, China, and Gembloux, Belgium – May 19, 2026 – Full-Life Technologies (“Full-Life”, the “Company”), a fully-integrated global radiotherapeutics company, today announced the completion of a US$150 million financing package, comprised of approximately US$109 million…
INDIANAPOLIS and NEW YORK and CAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. (“Ajax”), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative…
SHANGHAI, China, April 10, 2026 – Oricell Therapeutics Holdings Limited (“Oricell”), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the closing of a pre-IPO financing round in excess of $110 million. The…
SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Soleno Therapeutics, Inc. (Nasdaq: SLNO) today announced that Neurocrine has entered into a definitive agreement to acquire Soleno…
RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology…
GALWAY, Ireland, March 10, 2026 /PRNewswire/ — Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at…
Montreal, QC, Canada (Feb 25, 2026) – 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announced it has entered into an agreement with GSK plc (GSK), under…
BOSTON, MA, January 10, 2026 — Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing a novel and differentiated inhaled therapeutic candidate to treat serious respiratory diseases, today announced the closing of a $103 million Series B…
DUBLIN, Nov. 19, 2025 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) (“Alkermes”) and Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel”) today announced that the companies have reached agreement on the terms of an increased recommended offer under…